Efficacy and Safety Study of Bilateral IVT Injection of GS010 at Two Dose Levels in LHON Patients
← catalyst calendarNCT07303296 · readout in 634 d
Sponsored by GenSight Biologics (industry) · SIGHT.PA — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
14estimated
Sites
1
Country
France
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-22 | actual | When the study began enrolling |
| Primary completion | 2028-05-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Leber Hereditary Optic Disease
Interventions
- Genetic: GS010 High dose — also filed as Lumevoq, GS010, lenadogene nolparvovec
- Genetic: GS010 Low dose — also filed as GS010, Lenadogene nolparvovec, Lumevoq
Primary outcome
what the primary-completion date above is the date OFThe primary endpoint will be the BCVA change from baseline to 1.5 years post-treatment in the study eyes.
measured from baseline to 1.5 years post-treatment
Permalink · SIGHT.PA's whole pipeline · Catalyst calendar · Every registered study · What changed